Literature DB >> 18845354

siRNA targeting VEGF inhibits hepatocellular carcinoma growth and tumor angiogenesis in vivo.

Esther Raskopf1, Annabelle Vogt, Tilman Sauerbruch, Volker Schmitz.   

Abstract

BACKGROUND/AIMS: We have investigated whether siRNA targeted against VEGF inhibits functional properties of endothelial cells in vitro and HCC tumor growth and blood vessel formation in vivo.
METHODS: The influence of siRNA-VEGF on endothelial cell proliferation, apoptosis and tube formation were analyzed in vitro. Antitumoral effects were examined in an orthotopic tumor model after ex vivo transfer or intraperitoneal treatment of siRNA, respectively. Intratumoral microvessel density was assessed by CD31 staining.
RESULTS: VEGF expression was inhibited in Hepa129 by 70% and in SVEC4-10 by 48% within two days after transfection. In vitro, endothelial cell proliferation and tube formation was reduced by 23% and 38%, respectively. Interference with VEGF signaling was demonstrated by reduced pAKT in hepatoma cells. Tumor growth was inhibited by ex vivo transfer or intraperitoneal application of siRNA-VEGF by 83% or 63% in orthotopic tumors within 14 days. VEGF protein was reduced in both models by 29% and 44%. Microvessel density dropped to 34% for tumors from ex vivo transfected cells and 39% for systemic treated tumors.
CONCLUSIONS: The results show that VEGF knockdown can be associated with reduced endothelial cell proliferation and tube formation in vitro and decreased tumor growth and microvessel density in vivo.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18845354     DOI: 10.1016/j.jhep.2008.07.022

Source DB:  PubMed          Journal:  J Hepatol        ISSN: 0168-8278            Impact factor:   25.083


  33 in total

1.  Suppression of vascular endothelial growth factor via siRNA interference modulates the biological behavior of human nasopharyngeal carcinoma cells.

Authors:  Hai B Zhou; Yi F Yin; Yan Hu; Xin Li; Li Y Zou; Yong J Li; Yu Gu; Bao Q Ou; Juan Fu; Jun H Du; Gang Wu
Journal:  Jpn J Radiol       Date:  2011-09-29       Impact factor: 2.374

2.  Overexpression of the RNA binding protein HuR impairs tumor growth in triple negative breast cancer associated with deficient angiogenesis.

Authors:  Matthew M Gubin; Robert Calaluce; J Wade Davis; Joseph D Magee; Connie S Strouse; Daniel P Shaw; Lixin Ma; Ashley Brown; Timothy Hoffman; Tammy L Rold; Ulus Atasoy
Journal:  Cell Cycle       Date:  2010-08-17       Impact factor: 4.534

3.  FOXO1 modulates osteoblast differentiation.

Authors:  Michelle F Siqueira; Stephen Flowers; Rupa Bhattacharya; Dan Faibish; Yugal Behl; Darrell N Kotton; Lou Gerstenfeld; Elizabeth Moran; Dana T Graves
Journal:  Bone       Date:  2011-01-28       Impact factor: 4.398

4.  Small interfering RNAs induce target-independent inhibition of tumor growth and vasculature remodeling in a mouse model of hepatocellular carcinoma.

Authors:  Mathieu Bergé; Philippe Bonnin; Eric Sulpice; José Vilar; David Allanic; Jean-Sébastien Silvestre; Bernard I Lévy; Gordon C Tucker; Gérard Tobelem; Tatyana Merkulova-Rainon
Journal:  Am J Pathol       Date:  2010-10-22       Impact factor: 4.307

5.  Role of hypoxia-inducible transcription factor 1alpha for progression and chemosensitivity of murine hepatocellular carcinoma.

Authors:  Katjana Daskalow; Nadine Rohwer; Esther Raskopf; Evelyne Dupuy; Anja Kühl; Christoph Loddenkemper; Bertram Wiedenmann; Volker Schmitz; Thorsten Cramer
Journal:  J Mol Med (Berl)       Date:  2010-04-12       Impact factor: 4.599

Review 6.  Signaling Pathways as Potential Therapeutic Targets in Hepatocarcinogenesis.

Authors:  Yeliz Yılmaz; Ayşim Güneş; Hande Topel; Neşe Atabey
Journal:  J Gastrointest Cancer       Date:  2017-09

7.  Anti-angiogenesis in hepatocellular carcinoma treatment: current evidence and future perspectives.

Authors:  Martin-Walter Welker; Joerg Trojan
Journal:  World J Gastroenterol       Date:  2011-07-14       Impact factor: 5.742

8.  Amentoflavone Inhibits Hepatocellular Carcinoma Progression Through Blockage of ERK/NF-ĸB Activation.

Authors:  Kun-Ching Lee; Wei-Ting Chen; Yu-Chang Liu; Song-Shei Lin; Fei-Ting Hsu
Journal:  In Vivo       Date:  2018 Sep-Oct       Impact factor: 2.155

Review 9.  Nanoparticles for targeted delivery of therapeutics and small interfering RNAs in hepatocellular carcinoma.

Authors:  Jaleh Varshosaz; Maryam Farzan
Journal:  World J Gastroenterol       Date:  2015-11-14       Impact factor: 5.742

10.  Low temperature of radiofrequency ablation at the target sites can facilitate rapid progression of residual hepatic VX2 carcinoma.

Authors:  Shan Ke; Xue-mei Ding; Jian Kong; Jun Gao; Shao-hong Wang; Yan Cheng; Wen-bing Sun
Journal:  J Transl Med       Date:  2010-07-29       Impact factor: 5.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.